Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Year: 2019
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
Authors: Gerald Falchook, Seth Rosen, Patricia LoRusso, Justin Watts, Shilpa Gupta, Catherine C. Coombs, Moshe Talpaz, Razelle Kurzrock, Monica Mita, Ryan Cassaday, Wael Harb, Julio Peguero, David C. Smith, Sarina A. Piha-Paul, Russ Szmulewitz, Marcus S. Noel, Swamy Yeleswaram, Phillip Liu, Julie Switzky, Gongfu Zhou, Fred Zheng, Amitkumar Mehta
Institutions: HealthONE, Yale University, Sylvester Comprehensive Cancer Center, University of Minnesota, University of North Carolina at Chapel Hill, University of Michigan, University of California System, Cedars-Sinai Medical Center, University of Washington, Fred Hutch Cancer Center, Horizon Oncology Center, The University of Texas MD Anderson Cancer Center, University of Chicago Medical Center, University of Rochester Medicine, University of Rochester, Incyte (United States), University of Alabama at Birmingham
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2973850435